Avid Bioservices Inc (CDMO)

[biopharm]

IIS increases again...now to 43.65% and with others from Ken Dart to others to strong hold retail we will be over 85% SOON

As we wait for the official confirmation for Avid CDMO BOD that expansion is required, Mr Baird will be at Watertown MA town hall meeting this evening re: 650 Pleasant St for new CDMO "Arranta" backed by Ampersand Capital and would Ampersand be backing all these NEW CDMOs with no forward guidance due to Avid Bioservices CDMO negotiations with ThermoFisher etc etc with Subcutaneous approvals around the corner ? What stops Bamforth from illegal activities to divert just a handful of clients to Arranta and leave Avid CDMO not needing expansion? ALL EYES are watching Mr Bamforth : ) ...from many directions and perfectly legal for the town to know ALL chemicals heading into such facilities

Omeros...PS Targeting en route and more to come, Targeting of PS requires no more Targeting of a dozen+ PS receptors and many questions directed to FDA and Federal Authorities
Don't put it past a backup plan for the Targeting of several receptors via Betabodies and remember, Betabodies Trademark etc NOT EXCLUSIVE to Bavituximab

Betabodies had been around 10+ years and NO PUBLIC research has been seen YET

Omeros 10k filed Nov 12, 2019 includes PS Targeting and compare this to ALL prior known MOA ( as we knew it then ) of PS Targeting and below is 100% PS Targeting

Ex Peregrine CEO Steve King had a PS Targeting PLATFORM and PROGRAMS as well ....where those collaborations were never disclosed ...hmmm
_______

Page 23

GPCR Platform and Programs. We have developed a proprietary cellular redistribution assay which we use in a high- throughput manner to identify synthetic ligands, including antagonists, agonists and inverse agonists, that bind to and affect the function of orphan GPCRs. We are conducting in vitro and in vivo preclinical efficacy studies and optimizing compounds for a number of targets. One of our priorities in this program is GPR174. In ex vivo human studies, our small-molecule inhibitors targeting GPR174 upregulate the production of cytokines (e.g., IL-2, interferon-?), block multiple checkpoints (e.g., PDL-1, CTLA-4, LAG-3) and tumor promoters (e.g., amphiregulin), and suppress regulatory T-cells. Based on our data, we believe that GPR174 controls a major pathway in cancer and modulation of the receptor could provide a seminal advance in immuno-oncologic treatments for a wide range of tumors. Our recent discoveries suggest a new approach to cancer immunotherapy that targets inhibition of GPR174 and can be combined with and significantly improve the tumor-killing effects of adenosine pathway inhibitors. These discoveries include (i) identification of cancer-immunity pathways controlled by GPR174, (ii) the identification of phosphatidylserine as a natural ligand for GPR174, (iii) a collection of novel small-molecule inhibitors of GPR174 and (iv) a synergistic enhancement of “tumor-fighting” cytokine production by T cells following the combined inhibition of both GPR174 and the adenosine pathway (e.g., A2A and/or A2B), another key metabolic pathway that regulates tumor immunity. We continue to focus on GPR174 and several other of our GPCR targets with the objective of moving compounds targeting them into human trials.


https://investor.omeros.com/static-files/f47dc3ec-d19f-4adf-8e65-f06c9627d91e